Peer Exchange

Treating Hyperhidrosis: Glycopyrronium Tosylate
August 17, 2018 – 
Shawn Davis, PharmD, highlights the potential for treating primary axillary hyperhidrosis with glycopyrronium tosylate, an emerging treatment option.
Emerging Therapies: Glycopyrronium Tosylate
August 17, 2018 – 
Dee Anna Glaser, MD; Adelaide Hebert, MD; and Andy Szczotka, PharmD, discuss an emerging therapy, glycopyrronium tosylate, highlighting its anticipated indication, towelette formulation, and clinical study data showing its safety, efficacy, and benefit to patients.
Coverage of Current Therapies in Hyperhidrosis
August 10, 2018 – 
Shawn Davis, PharmD, reviews payer considerations for covering treatment options in hyperhidrosis.
Goals of Therapy in Treating Hyperhidrosis
August 03, 2018 – 
Dee Anna Glaser, MD; Adelaide Hebert, MD; and Adam Friedman, MD, FAAD, highlight the International Hyperhidrosis Society’s goals for educating clinicians and patients about hyperhidrosis, as well as the importance of patient-oriented treatment.
Recognizing Hyperhidrosis as a Medical Condition
July 23, 2018 – 
Shawn Davis, PharmD, remarks on the importance of recognizing hyperhidrosis as a medical condition, highlighting strategies for raising awareness within the managed care community.
Diagnosing Hyperhidrosis
July 23, 2018 – 
Dee Anna Glaser, MD; Adam Friedman, MD, FAAD; Adelaide Hebert, MD; and Andy Szczotka, PharmD, discuss how to diagnosis hyperhidrosis and identify areas for improvement in educating primary care physicians about diagnosing and treating hyperhidrosis, as well as educating payers about the condition.
Current Considerations in Managing Hyperhidrosis
June 29, 2018 – 
Shawn Davis, PharmD, defines hyperhidrosis and remarks on current limitations in recognizing it as a clinical condition.
Types of Hyperhidrosis
June 29, 2018 – 
Dee Anna Glaser, MD; Adelaide Hebert, MD; and Adam Friedman, MD, FAAD, outline the signs and symptoms of hyperhidrosis and differentiate between the primary focal and secondary generalized types.
Determining Cost-Effectiveness of Newer HIV Therapies
April 02, 2018 – 
Michael G. Sension, MD; Peter L. Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; and Elly Fatehi, PharmD, MPH, offer their perspectives on the challenges with determining the cost effectiveness of newer HIV therapies versus existing therapies.
Emerging Therapies in HIV
March 26, 2018 – 
Peter L. Salgo, MD; Michael G. Sension, MD; Jeffrey D. Dunn, PharmD, MBA; and Elly Fatehi, PharmD, MPH, discuss emerging therapies in HIV and the impact that effective therapies have had on sense of urgency.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
×

Sign In

Not a member? Sign up now!